Brief: Landos Biopharma Reports Positive Top-Line Results From NX-13 Phase 1B Trial

Landos Biopharma

03/08/2022 13:50

Aug 3 (Reuters) - Landos Biopharma Inc  LABP.O :
    * LANDOS BIOPHARMA REPORTS POSITIVE TOP-LINE RESULTS FROM
NX-13
PHASE 1B TRIAL
    * LANDOS BIOPHARMA INC - NX-13 DEMONSTRATED FAVORABLE SAFETY
AND
TOLERABILITY PROFILE ACROSS RANGE OF ONCE-DAILY DOSES
    * LANDOS BIOPHARMA INC - RESULTS INDICATE PROMISING EARLY
SIGNALS
REGARDING EFFICACY OF NX-13
    * LANDOS BIOPHARMA INC - PHASE 2 PROOF OF CONCEPT CLINICAL
TRIAL
IN ULCERATIVE COLITIS PLANNED
    * LANDOS BIOPHARMA INC - PLANS TO INITIATE A PHASE 2
CLINICAL
TRIAL TO EVALUATE SAFETY, EFFICACY, AND OPTIMAL DOSING OF NX-13
IN UC PATIENTS

Source text for Eikon:  ID:nGNX48wnH8 
Further company coverage:  LABP.O